Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors

Leuk Lymphoma. 2017 Jan;58(1):218-221. doi: 10.1080/10428194.2016.1180684. Epub 2016 May 17.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Boron Compounds / pharmacology
  • Bortezomib / pharmacology
  • Drug Resistance, Neoplasm / genetics*
  • Gene Expression Profiling / methods*
  • Glycine / analogs & derivatives
  • Glycine / pharmacology
  • Histone Deacetylase Inhibitors / pharmacology*
  • Humans
  • Hydroxamic Acids / pharmacology
  • Lymphoma, Large B-Cell, Diffuse / drug therapy
  • Lymphoma, Large B-Cell, Diffuse / genetics
  • Lymphoma, Large B-Cell, Diffuse / metabolism
  • Male
  • Mice, SCID
  • Prognosis
  • Proteasome Inhibitors / pharmacology*
  • U937 Cells
  • Vorinostat
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents
  • Boron Compounds
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • MLN2238
  • Proteasome Inhibitors
  • Vorinostat
  • Bortezomib
  • Glycine